
Ulisse
UBM.MIUlisse Biomed S.p.A. Price (UBM.MI)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
21,569,800
(167.4618)%Income Statement Summary
Revenue | |
Cost of Revenue | |
Gross Profit | |
Operating Expenses | |
Operating Income | |
Other Expenses | |
Net Income |


Income Statement
Ulisse Biomed S.p.A.Currency: EUR
YEAR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||
Revenue |
76.00
+0% |
11,000.00
+14,374% |
429,000.00
+3,800% |
276,628.00
-36% |
138,437.00
-50% |
66,208.00
-52% |
|||||||||||||
Cost of Revenue | |||||||||||||||||||
Cost of Revenue | 45,982.00 | 711,000.00 | 229,000.00 | 934,378.00 | 1,682,825.00 | 1,615,266.00 | |||||||||||||
Gross Profit | |||||||||||||||||||
Gross Profit |
-45,906.00
+0% |
-700,000.00
+1,425% |
200,000.00
-129% |
-657,750.00
-429% |
-1,544,388.00
+135% |
-1,549,058.00
+0% |
|||||||||||||
Gross Profit Ratio | (-604.03%) | (-63.64%) | (0.47%) | (-2.38%) | (-11.16%) | (-23.40%) | |||||||||||||
Operating Expenses | |||||||||||||||||||
Research and Development | 0.00 | 0.00 | 273,971.00 | 243,100.00 | 504,321.00 | 1,300,321.00 | |||||||||||||
General and Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||
Selling, General & Admin... | 1,415,296.00 | 189,658.00 | -196,973.00 | -162,497.00 | -348,237.00 | 609,711.00 | |||||||||||||
Selling & Marketing Exp... | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||
Depreciation and Amortiz... | 45,982.00 | 55,632.00 | 50,857.00 | 247,720.00 | 319,639.00 | 2,654,340.00 | |||||||||||||
Other Expenses | -401,160.00 | 417,000.00 | 80,000.00 | 0.00 | 0.00 | 0.00 | |||||||||||||
Total Operating Expenses | 1,816,456.00 | 417,000.00 | 80,000.00 | 80,603.00 | 156,084.00 | 1,910,032.00 | |||||||||||||
Cost and Exponses | 1,862,435.00 | 1,128,000.00 | 309,000.00 | 1,014,980.00 | 1,838,909.00 | 3,525,298.00 | |||||||||||||
Operating Income | |||||||||||||||||||
Operating Income |
-1,862,440.00
+0% |
-1,116,000.00
-40% |
120,000.00
-111% |
-738,350.00
-715% |
-1,700,470.00
+130% |
-3,459,090.00
+103% |
|||||||||||||
Operating Income Ratio | (-24,505.79%) | (-101.45%) | (0.28%) | (-2.67%) | (-12.28%) | (-52.25%) | |||||||||||||
Other Income and Exp... | |||||||||||||||||||
Interest Income | 26.00 | 0.00 | 0.00 | 0.00 | 48.00 | 191.00 | |||||||||||||
Interest Expenses | 0.00 | 0.00 | 0.00 | 206.00 | 164.00 | 139.00 | |||||||||||||
Total Other Income/Exp... | -71,048.00 | 211,433.00 | 104,000.00 | 134,751.00 | 392,725.00 | -1,337,757.00 | |||||||||||||
EBITDA | |||||||||||||||||||
EBITDA | -1,601,461.00 | -1,043,000.00 | 275,071.00 | -355,673.00 | -987,945.00 | -2,142,368.00 | |||||||||||||
EBITDA ratio | (-23,900.79%) | (-96.45%) | (0.40%) | (-1.77%) | (-9.97%) | (-32.36%) | |||||||||||||
Income Before Tax | |||||||||||||||||||
Income Before Tax | -1,933,483.00 | -1,098,000.00 | 224,000.00 | -603,599.00 | -1,307,745.00 | -4,796,847.00 | |||||||||||||
Income Before Tax Ratio | (-25,440.57%) | (-99.82%) | (0.52%) | (-2.18%) | (-9.45%) | (-72.45%) | |||||||||||||
Income Tax Expense | |||||||||||||||||||
Income Tax Expense | -2.00 | -18,000.00 | 2,000.00 | 0.00 | 1.00 | 0.00 | |||||||||||||
Net Income | |||||||||||||||||||
Net Income | -1,933,483.00
+0% |
-1,080,000.00
-44% |
222,000.00
-121% |
-603,599.00
-372% |
-1,307,745.00
+117% |
-4,796,847.00
+267% |
|||||||||||||
Net Income Ratio | (-25,440.57%) | (-98.18%) | (0.52%) | (-2.18%) | (-9.45%) | (-72.45%) | |||||||||||||
Earning Per Share | |||||||||||||||||||
Basic EPS | -0.27 | -0.15 | 0.03 | -0.07 | -0.16 | -0.22 | |||||||||||||
Diluted EPS | -0.27 | -0.15 | 0.03 | -0.07 | -0.16 | -0.22 | |||||||||||||
Share Outstanding | |||||||||||||||||||
Basic Share Outstanding | 7,250,000.00 | 7,250,000.00 | 7,250,000.00 | 8,063,750.00 | 8,064,629.00 | 21,569,800.00 | |||||||||||||
Diluted Share Outstanding | 7,250,000.00 | 7,250,000.00 | 7,250,000.00 | 8,063,750.00 | 8,064,629.00 | 21,569,800.00 |